OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil device, a localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company operates in one segment being the device development for new medical treatments. Geographically, it derives maximum revenue from Europe and the rest from Australia, the Middle East, and the United Kingdom.
Contact
7 Eden Park Drive
Level 5, Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,740.48 | 70.78 | -0.91% |
| DAX 40 | 25,111.26 | 260.49 | -1.03% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,656.46 | 68.57 | -0.64% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |